Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations

Table 2

Baseline characteristics of 24 patients with EGFR double mutations who received EGFR-TKI therapy.

Characteristics	Total; (%)	19Del + L858R; (%)	19Del + T790M; (%)	L858R + T790M; (%)
Age (years)
<60	14 (58.3%)	5 (45.5%)	6 (75%)	3 (60%)
≥60	10 (41.7%)	6 (54.5%)	2 (25%)	2 (40%)
Smoking
Yes	8 (33.3%)	7 (63.6%)	0 (0%)	1 (20%)
No	16 (66.7%)	4 (36.4%)	8 (100%)	4 (80%)
ECOG PS
0-1	20 (83.3%)	8 (72.7%)	7 (87.5%)	5 (100%)
2	4 (16.7%)	3 (27.3%)	1 (12.5%)	0 (0%)
Gender
Male	13 (54.2%)	9 (81.8%)	3 (37.5%)	1 (20%)
Female	11 (45.8%)	2 (18.2%)	5 (62.5%)	4 (80%)
EGFR-TKI line
First-line	10 (41.7%)	6 (54.5%)	2 (25%)	2 (40%)
After first-line	14 (58.3%)	5 (45.5%)	6 (75%)	3 (60%)
Pathology
Adenocarcinoma	23 (95.8%)	11 (100%)	7 (87.5%)	5 (100%)
Squamous carcinoma	1 (4.2%)	0 (0%)	1 (12.5%)	0 (0%)